Mesoblast’s Cell Therapy For Pediatric GVHD Gets US Panel Green Light Despite FDA's "Substantial Concerns"

 
• By Brenda Sandburg
  
gvhd concept words isometric 3d word text concept with some related text and dot connected - vector
Mesoblast's remestemcel-L data is sufficient to support efficacy, FDA panel concludes • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers